|Mode of transmission||Zoster is a reactivation of the varicella zoster virus in someone who has previously had varicella disease. |
Contact with zoster vesicles can cause varicella in non-immune individuals. Some airborne spread may be possible from immune-compromised patients.
|Period of communicability||Until lesions have crusted.|
|Burden of disease||Increasing incidence with age; lifetime risk about 1 in 3.|
|Vaccine||Zoster vaccine (Zostavax), a higher titre formulation of the live attenuated varicella vaccine. |
Do not give to children.
|Recommended immunisation schedule||One dose for adults aged 50 years and older.|
|Vaccine efficacy/effectiveness||Reduces the burden of zoster illness: by 61 percent in all adults aged over 60 years, by 65.5 percent in those aged 60–69 years and by 55.4 percent in those aged 70 years and older.|
|Contraindications||Certain immune deficiency states – consult the individual’s specialist for advice. |
Known systemic hypersensitivity to neomycin.
Active untreated tuberculosis.